Acute Lymphoblastic Leukemia (ALL) Clinical Trials


CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia

Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
Sponsor:   David Miklos
Not yet recruiting - verified July 2017

Learn More

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission

Condition:   Childhood Acute Lymphoblastic Leukemia in Remission
Interventions:   Other: Educational Intervention;   Other: Internet-Based Intervention;   Other: Internet-Based Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified July 2017

Learn More

Leukapheresis for CAR-Therapy Manufacturing

Conditions:   Leukemia;   Lymphoma;   Acute Lymphoblastic Leukemia;   Diffuse Large B-Cell Lymphoma;   Non-Hodgkin's Lymphoma
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified July 18, 2017

Learn More

Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition:   Acute Lymphoblastic Leukemia
Interventions:   Drug: Ponatinib;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Rituximab;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: G-CSF;   Drug: Methotrexate (intrathecally);   Drug: Cytarabine (intrathecally);   Drug: Methotrexate;   Drug: Cytarabine
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Not yet recruiting - verified July 2017

Learn More

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphocytic, Acute
Intervention:   Drug: DS-3201b
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified July 2017

Learn More

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Condition:   Acute Lymphoblastic Leukemia, Pediatric
Interventions:   Drug: Pegaspargase;   Drug: Erwinia asparaginase;   Drug: Cyclophosphamide;   Drug: CYTARABINE;   Drug: DASATINIB;   Drug: DEXAMETHASONE;   Drug: Dexrazoxane;   Drug: Doxorubicin;   Drug: ETOPOSIDE;   Drug: HYDROCORTISONE;   Drug: LEUCOVORIN CALCIUM;   Drug: MERCAPTOPURINE;   Drug: METHOTREXATE;   Drug: NELARABINE;   Drug: Vincristine
Sponsors:   Dana-Farber Cancer Institute;   Baxalta US Inc.
Recruiting - verified July 2017

Learn More

Treg Cell With IL-2 to Suppress aGVHD Umbilical Cord Blood Transplantation

Conditions:   Acute Lymphoblastic Leukemia;   Burkitt Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Large-cell Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Hodgkin Lymphoma;   Multiple Myeloma;   Acute Myelogenous Leukemia;   Biphenotypic Leukemia;   Undifferentiated Leukemia
Intervention:   Biological: Infusion of Treg
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2017

Learn More

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Conditions:   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   CD19-Positive Neoplastic Cells Present;   Mixed Phenotype Acute Leukemia;   Mixed Phenotype Acute Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions:   Biological: Blinatumomab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Conditions:   Acute Leukemia of Ambiguous Lineage;   Childhood B Acute Lymphoblastic Leukemia;   KMT2A Gene Rearrangement;   Mixed Phenotype Acute Leukemia
Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

Conditions:   T-Acute Lymphoblastic Leukemia;   Adult T Lymphoblastic Lymphoma
Interventions:   Drug: BL-8040;   Drug: Nelarabine
Sponsor:   Washington University School of Medicine
Recruiting - verified July 2017

Learn More

A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Condition:   Acute Lymphoblastic Leukemia
Intervention:   Biological: KTE-C19
Sponsor:   Kite Pharma, Inc.
Recruiting - verified July 2017

Learn More

A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Condition:   Acute Lymphoblastic Leukemia
Intervention:   Biological: KTE-C19
Sponsor:   Kite Pharma, Inc.
Recruiting - verified September 2016

Learn More

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Condition:   Acute Lymphoblastic Leukemia
Interventions:   Drug: ITMHA;   Drug: Dexamethasone;   Drug: Mitoxantrone;   Drug: Pegaspargase;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Bortezomib;   Drug: Vorinostat;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Vincristine
Sponsors:   St. Jude Children's Research Hospital;   Gateway for Cancer Research;   Texas Children's Hospital
Recruiting - verified May 2017

Learn More

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Conditions:   T-cell Acute Lymphoblastic Leukemia;   T-cell Lymphoblastic Lymphoma
Interventions:   Drug: LY3039478;   Drug: Dexamethasone;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified July 2017

Learn More

1-15 of 37
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.